Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 12/20 | 0.48 |
| ▸ | GSK3A | P49840 | 11/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550002 | 1.00 | AHR (0.48) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL30493623 | 0.82 | NPC1 (0.50) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL2233893 | 0.82 | NPC1 (0.50) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL3053419 | 0.79 | MAPT (0.53) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL5826323 | 0.78 | GSK3A (0.57) | GSK3BGSK3ACDK5CDK5R1CCNB2 | |
| SCHEMBL8484211 | 0.78 | CYP1A2 (0.56) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL10558162 | 0.78 | BRD4 (0.40) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL299769 | 0.77 | TDP2 (0.52) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL14852833 | 0.75 | GLO1 (0.43) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL673377 | 0.74 | CYP11B1 (0.42) | GSK3BGSK3ACDK5CDK5R1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653437-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Innovo Therapeutics Inc. (KR) | 2025-11-26 | — | — | EP | claimed |
| CN-118355015-A | N- (5-substituted- [ (1, 3, 4-thiadiazole) or (thiazolyl) ]) (substituted) carboxamide compounds for inhibiting human polymerase θ and uses thereof | 修复治疗公司 | 2024-07-16 | — | — | CN | claimed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | claimed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | claimed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | claimed |
| US-6048875-A | CARDIOVASCULAR DISORDERS; REDUCING THROMBOSIS | ADIR ET COMPAGNIE (FR) | 2000-04-11 | — | — | US | claimed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4737450-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| CN-121335899-A | Isoindolinone and dihydropyrrolo pyridone compounds and uses thereof | 溪砾科技股份有限公司 | 2026-01-13 | — | — | CN | disclosed |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-5478838-A | Treating hypertension, angina pectoris, asthma, improving peripheral circulation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0643716-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | THE PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0642520-A1 | THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0641781-A1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993024499-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024497-A1 | THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| EP-0556060-A1 | Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | AHR 4075/4885PDK2 627/4885GSK3B 1969/4885 |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNT2, RYR1 | AHR 2293/4885PDK2 1336/4885GSK3B 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.